title: Antiepileptic drugs alter endogenous retinoid concentrations: a possible mechanism of teratogenesis of anticonvulsant therapy.
abstract: The major antiepileptic drugs used for the control of seizures can induce developmental toxicity when administered during pregnancy. Vitamin A and retinoids are thought to control many processes of embryonic development including growth, differentiation and morphogenesis. We have therefore studied if the teratogenic action of antiepileptic agents could be mediated via alteration of the endogenous vitamin A--retinoid metabolism. Retinol and its oxidative metabolites all-trans-, 13-cis- and 13-cis-4-oxo-retinoic acid were measured in the plasma of 75 infants and children treated with various antiepileptic drugs for the control of seizures, and in 29 untreated controls of comparable age. Retinol levels increased with age, while the concentrations of retinoic acid compounds did not exhibit age-dependency. Valproic acid monotherapy increased retinol levels in the young age group and a trend toward increased retinol concentrations was also observed in all other patient groups. The plasma levels of the oxidative metabolites 13-cis- and 13-cis-4-oxo-retinoic acids were strongly decreased in all patient groups treated with phenytoin, phenobarbital, carbamazepine and ethosuximide, in combination with valproic acid, to levels which were below 1/3rd and 1/10th of corresponding control values, respectively. Little changes were observed with all-trans-retinoic acid except in one patient group treated with valproic acid/ethosuximide cotherapy where increased levels of this retinoid were found. Our study indicates that therapy with antiepileptic agents can have a profound effect on the endogenous retinoid metabolism. Because of the importance of retinoids for the signaling of crucial biological events during embryonic development, such altered retinoid metabolism may be highly significant in regard to antiepileptic drug teratogenesis.
authors.affiliation: Institut für Toxikologie und Embryopharmakologie, Freie Universität Berlin, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Nau
authors.forename: G
authors.initials: G
authors.lastname: Tzimas
authors.forename: M
authors.initials: M
authors.lastname: Mondry
authors.forename: C
authors.initials: C
authors.lastname: Plum
authors.forename: H L
authors.initials: HL
authors.lastname: Spohr
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000209:etiology*; D000927:Anticonvulsants / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D015474:Isotretinoin / Q000097:blood; D008297:Male; D010084:Oxidation-Reduction; D012176:Retinoids / Q000097:blood*; D012640:Seizures / Q000097:blood* / Q000188:drug therapy*; D014212:Tretinoin / Q000097:blood; D014801:Vitamin A / Q000097:blood
chemical_list: D000927:Anticonvulsants; D012176:Retinoids; D014801:Vitamin A; D014212:Tretinoin; D015474:Isotretinoin